Behandling med octreotidacetat kan medføre alvorlig hypoglykæmi hos patienter med insulinomer, og andre somatostatin analoger er kendt for at nedsætte glucose tolerance.
Therapy with octreotide acetate can produce severe hypoglycaemia in patients with insulinomas, and other somatostatin analogues are known to impair glucose tolerance.